Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only.

Oncology letters

Hertlein L, Rath J, Zeder-Göss C, Fürst S, Bayer D, Trillsch F, Mahner S, Burges A, Jeschke U.
PMID: 28927080
Oncol Lett. 2017 Sep;14(3):3302-3308. doi: 10.3892/ol.2017.6592. Epub 2017 Jul 18.

The present study aimed to identify differences in protein expression in cases of endometrioid endometrial cancer (EEC) with and without coexisting adenomyosis uteri (AM), and to evaluate the histopathological and prognostic distinctions. The total cohort included 22 patients in...

Cite
Hertlein L, Rath J, Zeder-Göss C, et al. Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncol Lett. 2017;14(3):3302-3308doi: 10.3892/ol.2017.6592.
Hertlein, L., Rath, J., Zeder-Göss, C., Fürst, S., Bayer, D., Trillsch, F., Mahner, S., Burges, A., & Jeschke, U. (2017). Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncology letters, 14(3), 3302-3308. https://doi.org/10.3892/ol.2017.6592
Hertlein, Linda, et al. "Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only." Oncology letters vol. 14,3 (2017): 3302-3308. doi: https://doi.org/10.3892/ol.2017.6592
Hertlein L, Rath J, Zeder-Göss C, Fürst S, Bayer D, Trillsch F, Mahner S, Burges A, Jeschke U. Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. Oncol Lett. 2017 Sep;14(3):3302-3308. doi: 10.3892/ol.2017.6592. Epub 2017 Jul 18. PMID: 28927080; PMCID: PMC5588003.
Copy Download .nbib Format: NLM
Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer.

Frontiers in oncology

Mahner S, Woelber L, Mueller V, Witzel I, Prieske K, Grimm D, Keller-V Amsberg G, Trillsch F.
PMID: 26500886
Front Oncol. 2015 Oct 05;5:211. doi: 10.3389/fonc.2015.00211. eCollection 2015.

In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellular receptors by the antibody aflibercept or the peptibody...

Cite
Mahner S, Woelber L, Mueller V, et al. Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. Front Oncol. 2015;5:211doi: 10.3389/fonc.2015.00211.
Mahner, S., Woelber, L., Mueller, V., Witzel, I., Prieske, K., Grimm, D., Keller-V Amsberg, G., & Trillsch, F. (2015). Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. Frontiers in oncology, 5211. https://doi.org/10.3389/fonc.2015.00211
Mahner, Sven, et al. "Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer." Frontiers in oncology vol. 5 (2015): 211. doi: https://doi.org/10.3389/fonc.2015.00211
Mahner S, Woelber L, Mueller V, Witzel I, Prieske K, Grimm D, Keller-V Amsberg G, Trillsch F. Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. Front Oncol. 2015 Oct 05;5:211. doi: 10.3389/fonc.2015.00211. eCollection 2015. PMID: 26500886; PMCID: PMC4593253.
Copy Download .nbib Format: NLM
Rotational state-dependent mixings between resonance states of vibrationally highly excited DCO (X2A').

The Journal of chemical physics

Wei J, Tröllsch A, Tesch C, Temps F.
PMID: 15268080
J Chem Phys. 2004 Jun 08;120(22):10530-42. doi: 10.1063/1.1724825.

Rotational state-dependent mixings between highly excited resonance states of DCO (X (2)A(')) were investigated by stimulated emission pumping spectroscopy via a series of intermediate rotational levels in the B (2)A(') electronic state of the radical. Two examples for such...

Cite
Wei J, Tröllsch A, Tesch C, et al. Rotational state-dependent mixings between resonance states of vibrationally highly excited DCO (X2A'). J Chem Phys. 2004;120(22):10530-42doi: 10.1063/1.1724825.
Wei, J., Tröllsch, A., Tesch, C., & Temps, F. (2004). Rotational state-dependent mixings between resonance states of vibrationally highly excited DCO (X2A'). The Journal of chemical physics, 120(22), 10530-42. https://doi.org/10.1063/1.1724825
Wei, J, et al. "Rotational state-dependent mixings between resonance states of vibrationally highly excited DCO (X2A')." The Journal of chemical physics vol. 120,22 (2004): 10530-42. doi: https://doi.org/10.1063/1.1724825
Wei J, Tröllsch A, Tesch C, Temps F. Rotational state-dependent mixings between resonance states of vibrationally highly excited DCO (X2A'). J Chem Phys. 2004 Jun 08;120(22):10530-42. doi: 10.1063/1.1724825. PMID: 15268080.
Copy Download .nbib Format: NLM
Management of patients with vulvar cancer: a perspective review according to tumour stage.

Therapeutic advances in medical oncology

Woelber L, Trillsch F, Kock L, Grimm D, Petersen C, Choschzick M, Jaenicke F, Mahner S.
PMID: 23634196
Ther Adv Med Oncol. 2013 May;5(3):183-92. doi: 10.1177/1758834012471699.

Treatment of patients with vulvar cancer is challenging for gynaecologic oncologists. Owing to the localization in a sensitive area, surgical radicality and the indication for adjuvant treatment have to be balanced with psychosocial aspects to treat patients adequately. Clinical...

Cite
Woelber L, Trillsch F, Kock L, et al. Management of patients with vulvar cancer: a perspective review according to tumour stage. Ther Adv Med Oncol. 2013;5(3):183-92doi: 10.1177/1758834012471699.
Woelber, L., Trillsch, F., Kock, L., Grimm, D., Petersen, C., Choschzick, M., Jaenicke, F., & Mahner, S. (2013). Management of patients with vulvar cancer: a perspective review according to tumour stage. Therapeutic advances in medical oncology, 5(3), 183-92. https://doi.org/10.1177/1758834012471699
Woelber, Linn, et al. "Management of patients with vulvar cancer: a perspective review according to tumour stage." Therapeutic advances in medical oncology vol. 5,3 (2013): 183-92. doi: https://doi.org/10.1177/1758834012471699
Woelber L, Trillsch F, Kock L, Grimm D, Petersen C, Choschzick M, Jaenicke F, Mahner S. Management of patients with vulvar cancer: a perspective review according to tumour stage. Ther Adv Med Oncol. 2013 May;5(3):183-92. doi: 10.1177/1758834012471699. PMID: 23634196; PMCID: PMC3630479.
Copy Download .nbib Format: NLM
Cooperation and opportunism in Galapagos sea lion hunting for shoaling fish.

Ecology and evolution

De Roy T, Espinoza ER, Trillmich F.
PMID: 34306617
Ecol Evol. 2021 Jun 21;11(14):9206-9216. doi: 10.1002/ece3.7807. eCollection 2021 Jul.

For predators, cooperation can decrease the cost of hunting and potentially augment the benefits. It can also make prey accessible that a single predator could not catch. The degree of cooperation varies substantially and may range from common attraction...

Cite
De Roy T, Espinoza ER, Trillmich F. Cooperation and opportunism in Galapagos sea lion hunting for shoaling fish. Ecol Evol. 2021;11(14):9206-9216doi: 10.1002/ece3.7807.
De Roy, T., Espinoza, E. R., & Trillmich, F. (2021). Cooperation and opportunism in Galapagos sea lion hunting for shoaling fish. Ecology and evolution, 11(14), 9206-9216. https://doi.org/10.1002/ece3.7807
De Roy, Tui, et al. "Cooperation and opportunism in Galapagos sea lion hunting for shoaling fish." Ecology and evolution vol. 11,14 (2021): 9206-9216. doi: https://doi.org/10.1002/ece3.7807
De Roy T, Espinoza ER, Trillmich F. Cooperation and opportunism in Galapagos sea lion hunting for shoaling fish. Ecol Evol. 2021 Jun 21;11(14):9206-9216. doi: 10.1002/ece3.7807. eCollection 2021 Jul. PMID: 34306617; PMCID: PMC8293783.
Copy Download .nbib Format: NLM
Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus.

Journal of ovarian research

Reichenbach J, Schmoeckel E, Mahner S, Trillsch F.
PMID: 34233728
J Ovarian Res. 2021 Jul 07;14(1):89. doi: 10.1186/s13048-021-00839-4.

BACKGROUND: For young borderline ovarian tumor (BOT) patients, preservation of the uterus was incorporated as an accepted option into treatment guidelines. For the endometrioid subtype (eBOT) however, adequate histological evaluation is challenging and might be associated with synchronous endometrial...

Cite
Reichenbach J, Schmoeckel E, Mahner S, et al. Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus. J Ovarian Res. 2021;14(1):89doi: 10.1186/s13048-021-00839-4.
Reichenbach, J., Schmoeckel, E., Mahner, S., & Trillsch, F. (2021). Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus. Journal of ovarian research, 14(1), 89. https://doi.org/10.1186/s13048-021-00839-4
Reichenbach, Juliane, et al. "Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus." Journal of ovarian research vol. 14,1 (2021): 89. doi: https://doi.org/10.1186/s13048-021-00839-4
Reichenbach J, Schmoeckel E, Mahner S, Trillsch F. Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus. J Ovarian Res. 2021 Jul 07;14(1):89. doi: 10.1186/s13048-021-00839-4. PMID: 34233728; PMCID: PMC8265084.
Copy Download .nbib Format: NLM
Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology.

Cancer management and research

Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Hester A, Zeder-Göß C, Kolben T, Burges A, Mahner S, Jeschke U, Trillsch F.
PMID: 31616183
Cancer Manag Res. 2019 Aug 14;11:7673-7684. doi: 10.2147/CMAR.S210004. eCollection 2019.

PURPOSE: This study aimed to investigate the potential prognostic impact of nuclear factor erythroid 2-related factor 2 (NRF2) and progesterone receptor A (PRA)/progesterone receptor B (PRB) in ovarian cancer patients which might be the rationale for putative new treatment...

Cite
Czogalla B, Kahaly M, Mayr D, et al. Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology. Cancer Manag Res. 2019;11:7673-7684doi: 10.2147/CMAR.S210004.
Czogalla, B., Kahaly, M., Mayr, D., Schmoeckel, E., Niesler, B., Hester, A., Zeder-Göß, C., Kolben, T., Burges, A., Mahner, S., Jeschke, U., & Trillsch, F. (2019). Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology. Cancer management and research, 117673-7684. https://doi.org/10.2147/CMAR.S210004
Czogalla, Bastian, et al. "Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology." Cancer management and research vol. 11 (2019): 7673-7684. doi: https://doi.org/10.2147/CMAR.S210004
Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Hester A, Zeder-Göß C, Kolben T, Burges A, Mahner S, Jeschke U, Trillsch F. Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology. Cancer Manag Res. 2019 Aug 14;11:7673-7684. doi: 10.2147/CMAR.S210004. eCollection 2019. PMID: 31616183; PMCID: PMC6699153.
Copy Download .nbib Format: NLM
Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gyneco-oncological center in Germany.

Archives of gynecology and obstetrics

Kaltofen T, Hagemann F, Harbeck N, Wuerstlein R, Kost BP, Burges A, Mahner S, Trillsch F.
PMID: 34491417
Arch Gynecol Obstet. 2021 Sep 07; doi: 10.1007/s00404-021-06211-7. Epub 2021 Sep 07.

PURPOSE: With the beginning of 2021, the world has been suffering from the COVID-19 pandemic for more than 1 year. More and more, we are able to evaluate side effects of the pandemic in the healthcare sector. A negative...

Cite
Kaltofen T, Hagemann F, Harbeck N, et al. Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gyneco-oncological center in Germany. Arch Gynecol Obstet. 2021;doi: 10.1007/s00404-021-06211-7.
Kaltofen, T., Hagemann, F., Harbeck, N., Wuerstlein, R., Kost, B. P., Burges, A., Mahner, S., & Trillsch, F. (2021). Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gyneco-oncological center in Germany. Archives of gynecology and obstetrics, . https://doi.org/10.1007/s00404-021-06211-7
Kaltofen, Till, et al. "Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gyneco-oncological center in Germany." Archives of gynecology and obstetrics vol. (2021). doi: https://doi.org/10.1007/s00404-021-06211-7
Kaltofen T, Hagemann F, Harbeck N, Wuerstlein R, Kost BP, Burges A, Mahner S, Trillsch F. Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gyneco-oncological center in Germany. Arch Gynecol Obstet. 2021 Sep 07; doi: 10.1007/s00404-021-06211-7. Epub 2021 Sep 07. PMID: 34491417; PMCID: PMC8422832.
Copy Download .nbib Format: NLM
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective.

Breast (Edinburgh, Scotland)

Forster M, Wuerstlein R, Koenig A, Amann N, Beyer S, Kaltofen T, Degenhardt T, Burges A, Trillsch F, Mahner S, Harbeck N, Chelariu-Raicu A.
PMID: 34736092
Breast. 2021 Oct 29;60:214-222. doi: 10.1016/j.breast.2021.10.012. Epub 2021 Oct 29.

INTRODUCTION: The side effects of systemic cancer therapy and the lack of clinical data on safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty among the patients about whether to get vaccinated or not. Here, we evaluated...

Cite
Forster M, Wuerstlein R, Koenig A, et al. COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective. Breast. 2021;60:214-222doi: 10.1016/j.breast.2021.10.012.
Forster, M., Wuerstlein, R., Koenig, A., Amann, N., Beyer, S., Kaltofen, T., Degenhardt, T., Burges, A., Trillsch, F., Mahner, S., Harbeck, N., & Chelariu-Raicu, A. (2021). COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective. Breast (Edinburgh, Scotland), 60214-222. https://doi.org/10.1016/j.breast.2021.10.012
Forster, Marie, et al. "COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective." Breast (Edinburgh, Scotland) vol. 60 (2021): 214-222. doi: https://doi.org/10.1016/j.breast.2021.10.012
Forster M, Wuerstlein R, Koenig A, Amann N, Beyer S, Kaltofen T, Degenhardt T, Burges A, Trillsch F, Mahner S, Harbeck N, Chelariu-Raicu A. COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective. Breast. 2021 Oct 29;60:214-222. doi: 10.1016/j.breast.2021.10.012. Epub 2021 Oct 29. PMID: 34736092; PMCID: PMC8555340.
Copy Download .nbib Format: NLM
Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer.

Translational oncology

Czogalla B, Partenheimer A, Badmann S, Schmoeckel E, Mayr D, Kolben T, Beyer S, Hester A, Burges A, Mahner S, Jeschke U, Trillsch F.
PMID: 33069100
Transl Oncol. 2021 Jan;14(1):100910. doi: 10.1016/j.tranon.2020.100910. Epub 2020 Oct 14.

BACKGROUND: Enolase-1, primarily known for its role in glucose metabolism, is overexpressed in various cancer entities. In contrast its alternative spliced nuclear isoform MBP-1 acts as a tumor suppressor. The aim of this study is to analyze the prognostic...

Cite
Czogalla B, Partenheimer A, Badmann S, et al. Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer. Transl Oncol. 2020;14(1):100910doi: 10.1016/j.tranon.2020.100910.
Czogalla, B., Partenheimer, A., Badmann, S., Schmoeckel, E., Mayr, D., Kolben, T., Beyer, S., Hester, A., Burges, A., Mahner, S., Jeschke, U., & Trillsch, F. (2021). Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer. Translational oncology, 14(1), 100910. https://doi.org/10.1016/j.tranon.2020.100910
Czogalla, Bastian, et al. "Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer." Translational oncology vol. 14,1 (2021): 100910. doi: https://doi.org/10.1016/j.tranon.2020.100910
Czogalla B, Partenheimer A, Badmann S, Schmoeckel E, Mayr D, Kolben T, Beyer S, Hester A, Burges A, Mahner S, Jeschke U, Trillsch F. Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer. Transl Oncol. 2021 Jan;14(1):100910. doi: 10.1016/j.tranon.2020.100910. Epub 2020 Oct 14. PMID: 33069100; PMCID: PMC7569221.
Copy Download .nbib Format: NLM
BODY SIZE AND SEXUAL SIZE DIMORPHISM IN MARINE IGUANAS FLUCTUATE AS A RESULT OF OPPOSING NATURAL AND SEXUAL SELECTION: AN ISLAND COMPARISON.

Evolution; international journal of organic evolution

Wikelski M, Trillmich F.
PMID: 28568579
Evolution. 1997 Jun;51(3):922-936. doi: 10.1111/j.1558-5646.1997.tb03673.x.

Body size is often assumed to represent the outcome of conflicting selection pressures of natural and sexual selection. Marine iguana (Amblyrhynchus cristatus) populations in the Galápagos exhibit 10-fold differences in body mass between island populations. There is also strong...

Cite
Wikelski M, Trillmich F. BODY SIZE AND SEXUAL SIZE DIMORPHISM IN MARINE IGUANAS FLUCTUATE AS A RESULT OF OPPOSING NATURAL AND SEXUAL SELECTION: AN ISLAND COMPARISON. Evolution. 1997;51(3):922-936doi: 10.1111/j.1558-5646.1997.tb03673.x.
Wikelski, M., & Trillmich, F. (1997). BODY SIZE AND SEXUAL SIZE DIMORPHISM IN MARINE IGUANAS FLUCTUATE AS A RESULT OF OPPOSING NATURAL AND SEXUAL SELECTION: AN ISLAND COMPARISON. Evolution; international journal of organic evolution, 51(3), 922-936. https://doi.org/10.1111/j.1558-5646.1997.tb03673.x
Wikelski, Martin, and Trillmich, Fritz. "BODY SIZE AND SEXUAL SIZE DIMORPHISM IN MARINE IGUANAS FLUCTUATE AS A RESULT OF OPPOSING NATURAL AND SEXUAL SELECTION: AN ISLAND COMPARISON." Evolution; international journal of organic evolution vol. 51,3 (1997): 922-936. doi: https://doi.org/10.1111/j.1558-5646.1997.tb03673.x
Wikelski M, Trillmich F. BODY SIZE AND SEXUAL SIZE DIMORPHISM IN MARINE IGUANAS FLUCTUATE AS A RESULT OF OPPOSING NATURAL AND SEXUAL SELECTION: AN ISLAND COMPARISON. Evolution. 1997 Jun;51(3):922-936. doi: 10.1111/j.1558-5646.1997.tb03673.x. PMID: 28568579.
Copy Download .nbib Format: NLM
Are endotherms emancipated? Some considerations on the cost of reproduction.

Oecologia

Trillmich F.
PMID: 28311628
Oecologia. 1986 Jul;69(4):631-633. doi: 10.1007/BF00410375.

No abstract available.

Cite
Trillmich F. Are endotherms emancipated? Some considerations on the cost of reproduction. Oecologia. 1986;69(4):631-633doi: 10.1007/BF00410375.
Trillmich, F. (1986). Are endotherms emancipated? Some considerations on the cost of reproduction. Oecologia, 69(4), 631-633. https://doi.org/10.1007/BF00410375
Trillmich, Fritz. "Are endotherms emancipated? Some considerations on the cost of reproduction." Oecologia vol. 69,4 (1986): 631-633. doi: https://doi.org/10.1007/BF00410375
Trillmich F. Are endotherms emancipated? Some considerations on the cost of reproduction. Oecologia. 1986 Jul;69(4):631-633. doi: 10.1007/BF00410375. PMID: 28311628.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries